首页> International journal of cancer> SRC inhibition represents a potential therapeutic strategy in liposarcoma.

SRC inhibition represents a potential therapeutic strategy in liposarcoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Elisabeth,Sievers

第一单位： Department of Pathology, University Hospital Cologne, Cologne, Germany.;Department of Pathology, University Hospital Bonn, Bonn, Germany.

作者： Elisabeth,Sievers ^[1] ; Marcel,Trautmann ^[2] ; Dagmar,Kindler ^[3] ; Sebastian,Huss ^[4] ; Inga,Gruenewald ^[4] ; Uta,Dirksen ^[5] ; Marcus,Renner ^[6] ; Gunhild,Mechtersheimer ^[6] ; Florence,Pedeutour ^[7] ; Pierre,Åman ^[8] ; Jun,Nishio ^[9] ; Hans-Ulrich,Schildhaus ^[10] ; Jutta,Kirfel ^[11] ; Peter,Schirmacher ^[6] ; Eva,Wardelmann ^[2] ; Reinhard,Buettner ^[3] ; Wolfgang,Hartmann ^[2]

作者单位： Department of Pathology, University Hospital Cologne, Cologne, Germany.;Department of Pathology, University Hospital Bonn, Bonn, Germany. ^[1] Department of Pathology, University Hospital Cologne, Cologne, Germany.;Department of Pathology, University Hospital Muenster, Muenster, Germany. ^[2] Department of Pathology, University Hospital Cologne, Cologne, Germany. ^[3] Department of Pathology, University Hospital Muenster, Muenster, Germany. ^[4] Department of Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany. ^[5] Department of Pathology, University Hospital Heidelberg, Heidelberg, Germany. ^[6] Laboratory of Solid Tumors Genetics, Nice University Hospital, Nice, France. ^[7] Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden. ^[8] Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. ^[9] Department of Pathology, University Hospital Goettingen, Goettingen, Germany. ^[10] Department of Pathology, University Hospital Bonn, Bonn, Germany. ^[11]

关键词 Dasatinib SRC liposarcoma siRNA